150 related articles for article (PubMed ID: 22335486)
1. Generation of human single-chain antibody to the CD99 cell surface determinant specifically recognizing Ewing's sarcoma tumor cells.
Gellini M; Ascione A; Flego M; Mallano A; Dupuis ML; Zamboni S; Terrinoni M; D'Alessio V; Manara MC; Scotlandi K; Picci P; Cianfriglia M
Curr Pharm Biotechnol; 2013; 14(4):449-63. PubMed ID: 22335486
[TBL] [Abstract][Full Text] [Related]
2. [Application of the in situ hybridization with EWS dual-color break-apart fluorescence probe and anti-CD99 and anti-FLI-1 antibodies in the diagnosis of Ewing's sarcoma/primitive neuroectodermal tumor].
Liu BY; Yang Y; DU J; Zhang Y; Wang H; Zheng J
Beijing Da Xue Xue Bao Yi Xue Ban; 2008 Aug; 40(4):358-62. PubMed ID: 18677380
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical detection of FLI-1 protein expression: a study of 132 round cell tumors with emphasis on CD99-positive mimics of Ewing's sarcoma/primitive neuroectodermal tumor.
Folpe AL; Hill CE; Parham DM; O'Shea PA; Weiss SW
Am J Surg Pathol; 2000 Dec; 24(12):1657-62. PubMed ID: 11117787
[TBL] [Abstract][Full Text] [Related]
4. Targeting CD99 in association with doxorubicin: an effective combined treatment for Ewing's sarcoma.
Scotlandi K; Perdichizzi S; Bernard G; Nicoletti G; Nanni P; Lollini PL; Curti A; Manara MC; Benini S; Bernard A; Picci P
Eur J Cancer; 2006 Jan; 42(1):91-6. PubMed ID: 16326096
[TBL] [Abstract][Full Text] [Related]
5. Biochemical and genetic characterization of the HBA71 Ewing's sarcoma cell surface antigen.
Fellinger EJ; Garin-Chesa P; Su SL; DeAngelis P; Lane JM; Rettig WJ
Cancer Res; 1991 Jan; 51(1):336-40. PubMed ID: 1988096
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic utility of FLI-1 monoclonal antibody and dual-colour, break-apart probe fluorescence in situ (FISH) analysis in Ewing's sarcoma/primitive neuroectodermal tumour (EWS/PNET). A comparative study with CD99 and FLI-1 polyclonal antibodies.
Mhawech-Fauceglia P; Herrmann F; Penetrante R; Beck A; Sait S; Block AM; Odunsi K; Fisher J; Balos L; Cheney RT
Histopathology; 2006 Dec; 49(6):569-75. PubMed ID: 17163841
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapies in Ewing's sarcoma.
Scotlandi K
Adv Exp Med Biol; 2006; 587():13-22. PubMed ID: 17163152
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical analysis of Ewing's sarcoma cell surface antigen p30/32MIC2.
Fellinger EJ; Garin-Chesa P; Triche TJ; Huvos AG; Rettig WJ
Am J Pathol; 1991 Aug; 139(2):317-25. PubMed ID: 1867320
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical profile of monoclonal antibody O13: antibody that recognizes glycoprotein p30/32MIC2 and is useful in diagnosing Ewing's sarcoma and peripheral neuroepithelioma.
Weidner N; Tjoe J
Am J Surg Pathol; 1994 May; 18(5):486-94. PubMed ID: 7513503
[TBL] [Abstract][Full Text] [Related]
10. Engagement of CD99 induces apoptosis through a calcineurin-independent pathway in Ewing's sarcoma cells.
Sohn HW; Choi EY; Kim SH; Lee IS; Chung DH; Sung UA; Hwang DH; Cho SS; Jun BH; Jang JJ; Chi JG; Park SH
Am J Pathol; 1998 Dec; 153(6):1937-45. PubMed ID: 9846983
[TBL] [Abstract][Full Text] [Related]
11. MIC2 detection in tumors of bone and adjacent soft tissues.
Devaney K; Abbondanzo SL; Shekitka KM; Wolov RB; Sweet DE
Clin Orthop Relat Res; 1995 Jan; (310):176-87. PubMed ID: 7641436
[TBL] [Abstract][Full Text] [Related]
12. Primary Ewing's sarcoma/primitive neuroectodermal tumor of the kidney: a clinicopathologic and immunohistochemical analysis of 11 cases.
Jimenez RE; Folpe AL; Lapham RL; Ro JY; O'Shea PA; Weiss SW; Amin MB
Am J Surg Pathol; 2002 Mar; 26(3):320-7. PubMed ID: 11859203
[TBL] [Abstract][Full Text] [Related]
13. Targeted imaging of Ewing sarcoma in preclinical models using a 64Cu-labeled anti-CD99 antibody.
O'Neill AF; Dearling JL; Wang Y; Tupper T; Sun Y; Aster JC; Calicchio ML; Perez-Atayde AR; Packard AB; Kung AL
Clin Cancer Res; 2014 Feb; 20(3):678-87. PubMed ID: 24218512
[TBL] [Abstract][Full Text] [Related]
14. CD99 engagement: an effective therapeutic strategy for Ewing tumors.
Scotlandi K; Baldini N; Cerisano V; Manara MC; Benini S; Serra M; Lollini PL; Nanni P; Nicoletti G; Bernard G; Bernard A; Picci P
Cancer Res; 2000 Sep; 60(18):5134-42. PubMed ID: 11016640
[TBL] [Abstract][Full Text] [Related]
15. Characterization and epitope mapping of two monoclonal antibodies against human CD99.
Gil MC; Lee MH; Seo JI; Choi YL; Kim MK; Jung KC; Park SH; Kim TJ
Exp Mol Med; 2002 Dec; 34(6):411-8. PubMed ID: 12526082
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of the pseudoautosomal gene MIC2 in Ewing's sarcoma and peripheral primitive neuroectodermal tumor.
Kovar H; Dworzak M; Strehl S; Schnell E; Ambros IM; Ambros PF; Gadner H
Oncogene; 1990 Jul; 5(7):1067-70. PubMed ID: 1695726
[TBL] [Abstract][Full Text] [Related]
17. Process development of a human recombinant diabody expressed in E. coli: engagement of CD99-induced apoptosis for target therapy in Ewing's sarcoma.
Moricoli D; Carbonella DC; Dominici S; Fiori V; Balducci MC; Guerzoni C; Manara MC; Pasello M; Laguardia ME; Cianfriglia M; Scotlandi K; Magnani M
Appl Microbiol Biotechnol; 2016 May; 100(9):3949-63. PubMed ID: 26685854
[TBL] [Abstract][Full Text] [Related]
18. Specificity and function of monoclonal antibodies directed against Ewing sarcoma cells.
Shi LR; Eichelbauer D; Borchard F; Jürgens H; Göbel U; Schneider EM
Cancer Immunol Immunother; 1994 Mar; 38(3):208-13. PubMed ID: 8124690
[TBL] [Abstract][Full Text] [Related]
19. Targeting Tumor Vascular CD99 Inhibits Tumor Growth.
Huijbers EJM; van der Werf IM; Faber LD; Sialino LD; van der Laan P; Holland HA; Cimpean AM; Thijssen VLJL; van Beijnum JR; Griffioen AW
Front Immunol; 2019; 10():651. PubMed ID: 31001265
[TBL] [Abstract][Full Text] [Related]
20. CD99 reactivity in mesenchymal chondrosarcoma.
Granter SR; Renshaw AA; Fletcher CD; Bhan AK; Rosenberg AE
Hum Pathol; 1996 Dec; 27(12):1273-6. PubMed ID: 8958297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
